Singular Genomics Sys Stock (NASDAQ: OMIC)

Dernières nouvelles pour Singular Genomics Sys (NASDAQ:OMIC) Stock

Singular Genomics Sys

Singular Genomics Systems Inc is a life science technology company that is leveraging novel next generation sequencing and multiomics technologies to build products that empower researchers and clinicians. The product development pipeline comprises two initial integrated solutions, each designed to leverage Sequencing Engine and purpose built to address different applications. The G4 Sequencing Platform is designed to target the NGS market. The PX Integrated Solution is designed to target the single cell, spatial analysis and proteomics markets. Both integrated solutions are used in many different and diverse market segments, including basic biology, oncology, immunology, neurology, genetic diseases, infectious diseases, the human microbiome and many others.

Singular Genomics Systems, Inc. - Common Stock

Singular Genomics Systems Inc

Scotiabank analyst George Farmer upgrades argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Sector Perform to Sector Outperform and raises the price target from $439 to $715.

News

Upgrades

Price Target

Analyst Ratings

ARGX

Scotiabank Upgrades argenx to Sector Outperform, Raises Price Target to $715

Earnings

Earnings Beats

Cummins Q3 2024 Adj. EPS $5.60 Beats $4.80 Estimate

<figure class="table"> 
<table>
<tbody>
<tr>
<td>Previous FY 2024 Guidance</td>
<td>Updated FY 2024 Guidance</td>
</tr>
<tr>
<td>Net Sales</td>
<td>$1.44 to $1.48 billion</td>
</tr>
<tr>
<td>Adjusted EBITDA1</td>
<td>$240 to $250 million</td>
</tr>
<tr>
<td>Free Cash Flow1</td>
<td>$100 to $120 million</td>
</tr>
</tbody>
</table>
</figure>
&nbsp;

Guidance

HLMN

Hillman Solutions Revised Its 2024 Revenue Guidance To $1.455B-$1.485B (From $1.44B-$1.48B) Vs $1.467B Est.; Free Cash Flow To $100M-$115M (Vs. $100M-$120M Prior)

These monthly dividends, which will be payable pursuant to the table below, total $0.75 per share for the first quarter of 2025 and represent a 2.0% increase from the regular monthly dividends declared for the fourth quarter of 2024 and a 4.2% increase from the regular monthly dividends paid in the first quarter of 2024.

Dividends

MAIN

Main Street Declares Supplemental Dividend Of $0.30 Per Share Payable In December 2024; Boosts Regular Monthly Dividends To $0.25 Per Share For Each Of January, February And March 2025

CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) reported quarterly earnings of $0.66 per share which beat the analyst consensus estimate of $0.51 by 29.41 percent. This is a 100 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $124.75 million which beat the analyst consensus estimate of $117.13 million by 6.51 percent. This is a 17.84 percent increase over sales of $105.86 million the same period last year.

PMTS

CPI Card Q3 Adj $0.66 Beats $0.51 Estimate, Sales $124.75M Beat $117.13M Estimate

2024 Outlook:
Based on its current forecast, Cummins is maintaining its full-year 2024 revenue guidance to be in the range of down 3% to flat. EBITDA is expected to be approximately 15.5%; at the top end of the previous guidance of 15.0% to 15.5%.
Cummins plans to continue generating strong operating cash flow and returns for shareholders and is committed to our long-term strategic goal of returning 50% of operating cash flow back to shareholders. In the near term, we will focus on reinvesting for profitable growth, dividends and reducing debt.

Cummins Affirms FY24 Sales Guidance Of $33.04B-$34.06B Vs, $33.60B Estimate

2024 guidance is as follows:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$950 million - $960 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Transaction costs</td>
<td colspan="1" rowspan="1">~16.0% of revenue</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Adjusted EBITDA (1)</td>
<td colspan="1" rowspan="1">$255 million to $265 million</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

PAYO

Payoneer Global Sees FY24 Revenue $950M-$960M (Prior $920M-$930M) Vs $928.71M Est.; Transaction Costs ~16.0% Of Revenue (Prior ~16.5%); Adjusted EBITDA $255M-$265M (Prior $225M-$235M)

2024&nbsp;Financial Outlook
Based on its current operating plans, Karyopharm has further narrowed its guidance for full year 2024 as follows:
<ul>
<li>Total revenue to be in the range of $145.0 million to $155.0 million as compared to the Company's prior guidance of $145.0 million to $160.0 million. Total revenue consists of U.S. XPOVIO net product revenue and license, royalty and milestone revenue earned from partners.</li>
<li>U.S. XPOVIO net product revenue to be in the range of $110.0 million to $115.0 million as compared to the Company's prior guidance of $105.0 million to $120.0 million.</li>
<li>R&amp;D and selling, general and administrative (SG&amp;A) expenses to be in the range of $255.0 million to $265.0 million, which includes approximately $20.0 million estimated non-cash stock-based compensation expense, as compared to the Company's prior guidance of $250.0 million to $265.0 million.</li>
<li>The Company expects that its existing cash, cash equivalents and investments, the revenue it expects to generate from XPOVIO net product sales and its license agreements and ongoing disciplined expense management and cost saving measures, will be sufficient to fund its planned operations into the first quarter of 2026.</li>
</ul>

Biotech

Health Care

General

KPTI

Karyopharm Expects 2024 Sales Of $145M-$155M Versus Prior Guidance Of $145M-$160M And Consensus Of $152.352M

Baird analyst Tristan Gerra maintains Navitas Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVTS#NASDAQ">NVTS</a>) with a Outperform and lowers the price target from $7 to $5.

NVTS

Baird Maintains Outperform on Navitas Semiconductor, Lowers Price Target to $5

LGI Homes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGIH#NASDAQ">LGIH</a>) reported quarterly earnings of $2.95 per share which beat the analyst consensus estimate of $2.54 by 16.14 percent. The company reported quarterly sales of $651.854 million which beat the analyst consensus estimate of $646.459 million by 0.83 percent. This is a 5.56 percent increase over sales of $617.539 million the same period last year.

LGIH

LGI Homes Q3 2024 GAAP EPS $2.95 Beats $2.54 Estimate, Sales $651.854M Beat $646.459M Estimate

Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is currently under investigation for potential tax fraud in France and the Netherlands. 
What Happened: The offices of the streaming giant were searched by investigators on Tuesday morning as part of a preliminary inquiry into alleged tax fraud and money laundering, reported Reuters.
The investigation, led by the French National Financial Prosecutor&#8217;s Office (PNF,) is focused on potential financial crimes and corruption. The probe, which began in November 2022, has led to searches at Netflix&#8217;s offices in central Paris and its European headquarters in Amsterdam.
A preliminary investigation in France does not automatically indicate that criminal charges will be filed or that a trial will occur.
See Also: <a href="https://www.benzinga.com/news/24/11/41703723/mark-cubans-million-dollar-advice-to-teens-if-i-were-16-again-id-start-this-lucrative-side-hustle?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mark Cuban&#8217;s Million-Dollar Advice To Teens: &#8216;If I Were 16 Again, I&#8217;d Start This Lucrative Side Hustle&#8217;</a>
Dutch authorities were simultaneously searching Netflix&#8217;s European headquarters in Amsterdam, according to the French judicial source. Neither Netflix France nor Netflix Netherlands have released a statement.
Netflix did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: In 2022, Netflix settled a tax dispute with Italy by paying 55.8 million euros ($60.78 million). The company, which opened its Paris office in 2020, produces most of its original films and series by working with third-party contractors.
This investigation comes at a time of significant change within Netflix. The company recently <a href="https://www.benzinga.com/news/24/10/41631621/netflix-restructures-leadership-bids-farewell-to-two-key-executives">restructured its leadership</a>, with the departure of two key executives, Rachel Whetstone, chief communications officer, and Dean Garfield, VP of public policy. This restructuring was part of a planned change announced by Co-CEO Ted Sarandos.
Price Action: Netflix stock, which has gained 61.26% so far this year, was down 0.2% during premarket trading on Tuesday, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41701405/dont-ever-use-this-word-around-mark-cuban-you-sound-stupid-because-youre-trying-to-sound-smart?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Don&#8217;t Ever Use This Word Around Mark Cuban: &#8216;You Sound Stupid &#8230; Because You&#8217;re Trying To Sound Smart&#8217;</a></li>
</ul>
This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Entertainment

Equities

Global

Markets

Tech

NFLX

Netflix In Hot Water As Tax Fraud Investigators Raid French, Dutch Offices: Report

CRGO

Freightos Welcomes Qantas Freight To WebCargo Platform, Enhancing Digital Booking Options Across Key Trans-Pacific Trade Routes

Keybanc analyst John Vinh maintains Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) with a Overweight and lowers the price target from $150 to $115.

SLAB

Keybanc Maintains Overweight on Silicon Laboratories, Lowers Price Target to $115

Hillman Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. The company reported quarterly sales of $393.300 million which beat the analyst consensus estimate of $387.780 million by 1.42 percent. This is a 1.41 percent decrease over sales of $398.943 million the same period last year.

Hillman Solutions Q3 2024 Adj. EPS $0.16, Inline, Sales $393.300M Beat $387.780M Estimate

LIND

Lindblad Expeditions Continues To See FY24 Tour Revenues Of $610M - $630M (Est $622.65M), Adjusted EBITDA  Of $88M - $98M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 13.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $38.78 million which beat the analyst consensus estimate of $37.79 million by 2.63 percent. This is a 7.70 percent increase over sales of $36.01 million the same period last year.

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) reported quarterly earnings of $5.86 per share which beat the analyst consensus estimate of $4.78 by 22.59 percent. This is a 27.67 percent increase over earnings of $4.59 per share from the same period last year. The company reported quarterly sales of $8.456 billion which beat the analyst consensus estimate of $8.294 billion by 1.96 percent. This is a 0.30 percent increase over sales of $8.431 billion the same period last year.

Cummins Q3 2024 GAAP EPS $5.86 Beats $4.78 Estimate, Sales $8.456B Beat $8.294B Estimate

Loop Capital analyst Rick Paterson downgrades Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from Buy to Hold and raises the price target from $22 to $22.5.

Downgrades

ATSG

Loop Capital Downgrades Air Transport Services Gr to Hold, Raises Price Target to $22.5

Payoneer Global Q3 2024 GAAP EPS $0.11 Beats $0.04 Estimate, Sales $248.274M Beat $225.476M Estimate

The FDA Has Extended The Target Action Date Of Its Review Of Organon's Supplemental New Drug Application For Vtama (Tapinarof) Cream, 1% For Atopic Dermatitis In Adults And Children Two Years Of Age And Older. The New Target Date Is March 12, 2025, Revised From The Original Target Action Date Of December 12

Singular Genomics announces 1-for-30 reverse stock split

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Singular Genomics Sys (NASDAQ:<a href="https://investorplace.com/stock-quotes/omic-stock-quote/">OMIC</a>) just reported results for the second quarter of 2023.<ul><li>Singular Genomics Sys reported earnings per share of -$10.50. This was above the analyst estimate for EPS of -$11.10.</li><li>The company reported revenue of $505,000.</li><li>This was 56.09% worse than the analyst estimate for revenue of $1.15 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/omic-stock-earnings-singular-genomics-sys-for-q2-of-2023/">OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Misses Revenue for Q2 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Misses Revenue for Q2 2023

Singular Genomics regains compliance with Nasdaq

Singular Genomics Systems GAAP EPS of -$8.57 beats by $0.29, revenue of $0.7M beats by $0.29M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Singular Genomics Sys (NASDAQ:<a href="https://investorplace.com/stock-quotes/omic-stock-quote/">OMIC</a>) just reported results for the second quarter of 2024.<ul><li>Singular Genomics Sys reported earnings per share of -$8.57. This was above the analyst estimate for EPS of -$8.88.</li><li>The company reported revenue of $737,000.</li><li>This was 84.25% better than the analyst estimate for revenue of $400,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/omic-stock-earnings-singular-genomics-sys-for-q2-of-2024/">OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

OMIC Stock Earnings: Singular Genomics Sys Beats EPS, Beats Revenue for Q2 2024

Singular Genomics Systems, Inc. 2024 Q2 - Results - Earnings Call Presentation

Singular Genomics Systems, Inc. (OMIC) Q2 2024 Earnings Call Transcript

Singular Genomics receives acquisition proposal from Deerfield

Singular Genomics jumps after Tang's Concentra offers $12 a share

Deals this week: Smartsheet, AT&T, BP, Cleveland-Cliffs, Vistra and more

AXNX

BATL

BLCO

BOOM

CACI

FLUT

INFN

MMSI

OMIC

PLTK

PYTCY

RVNC

SATS

SMAR

STZHF

VVPR

Press Releases

Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results

Singular Genomics to Report First Quarter 2024 Financial Results on May 14, 2024

Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results

Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference

Singular Genomics Announces 1-for-30 Reverse Stock Split

Singular Genomics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

Singular Genomics Receives Non-Binding Acquisition Proposal from Deerfield

Singular Genomics Receives Non-Binding Acquisition Proposal from Concentra Biosciences and Tang Capital

Comments

Singular Genomics Sys

Actualités

Dernières nouvelles pour Singular Genomics Sys (NASDAQ:OMIC) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL